Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2012

View Archived Issues

Danish company divulges novel CaS receptor agonists

Novel urate-lowering compound shows potential as a treatment for gout

Merck Serono patents new GM-CSF-directed immunotherapies

Results from several dapagliflozin trials disclosed

Famitinib metabolism investigated in clinical and in vitro studies

Novel oncolytic targets p53/Mdm2 interaction

Novel S1P1 receptor modulators reported by Allergan

Symbicort Turbuhaler obtains additional approval in Japan

Spanish group presents novel immunomodulators

Almirall develops new Janus kinase inhibitors

Stemergie Biotechnology discovers novel agents for cancer

Alexza provides update on Adasuve submissions

Ongoing meeting features presentations on PTHrP analogue for postmenopausal osteoporosis

Two phase III Flutiform trials meet primary endpoint

Repligen receives complete response letter for RG-1068 NDA

New agents for RSV infection disclosed by Biota Scientific Management

European CHMP adopts opinion on teduglutide

Genkyotex reports phase Ia data on GKT-137831

Novel prostanoid DP2 receptor antagonists designed in Spain

Astex kicks off phase II expansion segment of SGI-110 trial

Cellceutix clear to launch clinical development of anticancer drug

Theratechnologies gives update on tesamorelin regulatory progress

EMA committee issues opinion on taliglucerase alfa

Emend approved for additional indication in Japan

EMA committee recommends approval of intravenous cephalosporin antibiotic

Astellas Pharma set to launch Kiklin capsules in Japan

EMA committee issues opinion on Seebri Breezhaler

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...